Table 2

Family and clinical-related characteristics of the study participants in South Gondar zone, 1 August 2020–31 January 2021 (n=432)

VariablesFrequency (n=432)Percentage
Serostatus of sexual partner
 Positive22652.3
 Negative173.9
 Unknown18943.7
Disclosure status
 Not disclosed17741
 Disclosed25559
To whom serostatus disclosed
 Family7931
 Sexual partner17368.2
 Friend30.8
Stigma and discrimination
 No38789.6
 Yes4510.4
Do you use complementary medicine?
 No35181.3
 Yes8118.8
Do you use a reminder?
 No409.3
 Yes39290.7
Baseline CD4 count
 ≤500 cells/mm35113.2
 >500 cells/mm333686.8
Treatment regimens
 TDF+3 TC+EFV25960.0
 AZT+3 TC+EFV14333.1
 AZT+3 TC+NVP306.9
 TDF+3 TC+EFV25960.0
WHO clinical disease stage during initiation of ART
 Stage I5011.6
 Stage II35281.5
 Stage III306.9
Recent CD4 count
 ≤500 cells/mm38720.1
 >500 cells/mm334178.9
  • ART, antiretroviral therapy; AZT, Zidovudine; EFV, Efavirenz; NVP, Nevirapine; 3TC, Lamivudine; TDF, Tenofovir.